Fortress Biotech, Inc.

For the period ended Jan 13, 2026. Filed Jan 13, 2026.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Jan 13, 2026 · Filed Jan 13, 2026

Use the contents to explore the available documents and sections.

FBIO$1.85+0.5%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

EX-99.1 · Hematological Abnormalities

Hematological Abnormalities

Copper accumulation with ZYCUBO can result in spleen and bone marrow dysfunction as well as interference with iron metabolism. Anemia has been reported in patients taking ZYCUBO for Menkes disease. The healthcare team will perform periodic laboratory tests (complete blood count) before and during ZYCUBO administration. The dose of ZYCUBO may be adjusted as appropriate based on the results of the laboratory tests.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.